Progress of molecular targeted therapy for adenoid cystic carcinoma of salivary gland
10.3760/cma.j.cn115355-20220806-00505
- VernacularTitle:涎腺腺样囊性癌分子靶向治疗的研究进展
- Author:
Kaize HUANG
1
;
Yixiong REN
;
Wenge CHEN
Author Information
1. 山西医科大学口腔医学院，太原 030001
- Keywords:
Carcinoma, adenoid cystic;
Head and neck neoplasms;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2023;35(7):556-560
- CountryChina
- Language:Chinese
-
Abstract:
Adenoid cystic carcinoma (ACC) is a salivary gland malignant tumor which mainly occurs in the head, neck and the mammary gland, and is characterized with easy invasion of peripheral nerves, local easy recurrence after resection and painless distant metastasis. The treatment of ACC is usually based on surgical resection combined with postoperative radiotherapy. Patients with advanced disease usually cannot be cured, so far there is no ideal treatment regimen. Some studies have suggested that some targeted drugs show advantages in ACC patients who are insensitive or resistant to conventional therapy. This paper summarizes the research progress of molecular targeted therapy for ACC of salivary gland in order to provide new treatment options for ACC patients especially for those at advanced stage.
